100 likes | 193 Views
Corporate presentation January 2013. What we do. In depth technical expertise. Ithaka Track Record. >190 assignments completed for >90 clients Worked with >25 universities on technology commercialisation 9 university spin-outs created and financed >£30 million funding for clients
E N D
Corporate presentation January 2013
Ithaka Track Record • >190 assignments completed for >90 clients • Worked with >25 universities on technology commercialisation • 9 university spin-outs created and financed • >£30 million funding for clients • Venture capital, corporate deals and grants • Technical, commercial & IP evaluations undertaken for >30 organisations • Due diligence conducted for 9 investment funds • Unrivalled network of contacts
Ithaka Team • Paul Rodgers Founder & MD, experienced biotech entrepreneur, biomarkers & personalised medicine • John AdairBiopharmaceutical R&D (Axis Genetics, Scotgen, Celltech, Searle) • Richard Cumming Life science product development & marketing (Amersham, GE Healthcare) • Bill PrimroseDrug discovery & development (PanTherix, SioKem etc.) • Mark TreherneDrug discovery & development (Senexis, Cyclofluidic, BioFocus, Pfizer etc.) • Paula Wittels Medical devices & diagnostics (Pfizer, Quintiles etc.)
Ithaka: Corporate Clients creating a new cancer therapy
Typical Assignments • Business creation & sourcing finance • Psynova Neurotech & Smart Holograms • Technical, commercial and market evaluation • Newcastle University: biofilm prevention • Manchester University: novel medical implant device • Scottish Enterprise: medical device, anaesthesia • University of Bath: human and animal vaccine technology • Due diligence • Apposite (Anaphore), Finance Wales (ADCB) & Wellcome (Kymab) • Strategic advice • ThermoFisher, Smith & Nephew, Wellcome Genome Campus • Management, mentoring & coaching • ProteinLogic, Scottish Enterprise & Theryte • Portfolio review • Bloomsbury Bioseed Fund
Case Study: Psynova Neurotech • Biomarkers for psychiatric disorders • Potential applications in diagnostics, drug discovery and development • Ithaka role • Development of commercial strategy, business plan & securing of finance in 2007 • Paul Rodgers: chairman from 2007 to 2012 • Results • University spin-out company 2007 • > £8M investment & grant funding • First diagnostic product launched in 2010 • Commercial deal with Roche Pharmaceuticals Dec 2009 • Acquired by Myriad Genetics 2011
Why Work with Ithaka? • Personal experience • Technology commercialisation • New ventures • Fund raising • Growth through strategic partnerships • Across the life science spectrum • Multi-disciplinary team approach • Unique network of contacts • Support tailored to meet the client’s needs